The TAM family of receptor tyrosine kinases (RTKs), which includes TYRO3, AXL and MERTK, has emerged as new therapeutic target in many types of cancer, but their role in bladder cancer has not yet been determined. The gene discussed is AXL; the disease is urinary bladder cancer.